Omeros (NASDAQ:OMER) Cut to Sell at StockNews.com

StockNews.com downgraded shares of Omeros (NASDAQ:OMER) from a hold rating to a sell rating in a report released on Thursday.

Separately, Needham & Company LLC reaffirmed a hold rating on shares of Omeros in a research note on Tuesday, June 4th.

Omeros Price Performance

OMER opened at $4.12 on Thursday. Omeros has a 12 month low of $0.92 and a 12 month high of $5.68. The stock has a market capitalization of $238.73 million, a P/E ratio of -2.09 and a beta of 1.45. The business has a 50 day simple moving average of $4.34 and a 200-day simple moving average of $3.90.

Omeros (NASDAQ:OMER) last issued its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.13). Research analysts anticipate that Omeros will post -1.81 EPS for the current year.

Institutional Investors Weigh In On Omeros

Hedge funds and other institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC lifted its position in shares of Omeros by 199.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,069 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 5,378 shares during the last quarter. Cerity Partners LLC bought a new position in Omeros during the 4th quarter worth approximately $71,000. Oppenheimer & Co. Inc. acquired a new position in shares of Omeros in the 1st quarter worth approximately $85,000. Coldstream Capital Management Inc. increased its holdings in shares of Omeros by 42.1% in the 4th quarter. Coldstream Capital Management Inc. now owns 28,130 shares of the biopharmaceutical company’s stock valued at $92,000 after acquiring an additional 8,335 shares during the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its holdings in shares of Omeros by 200.0% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 30,000 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 20,000 shares during the period. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.